INTERNATIONAL NASH DAY

#StepUpforNASH

3

GLOBAL LIVER INSTITUTE

INTERNATIONAL NASH DAY
CONTENTS

1 Message from CEO, Donna R. Cryer, JD
2 Key Numbers
4 Endorsements
6 Partners
   List of Countries
   International Non-Governmental Organizations
   National Patients’ Organizations and Foundations
   Universities, Hospitals and Research Centers
   Additional Institutional Partners
10 NASH Day Videos
   Educational Panels
      Overview
      Panel Statistics
      Panels and Panelists
12 NASH Day Educational Panels
   Overview
   Panel Statistics
   Panels and Panelists
18 Digital Media Campaign and Statistics
   #NASHday
   Press Release
   Website
   Social Media Toolkit
23 Educational Materials
24 #NASHDay Highlights
   Global Liver Institute’s Liver Action Network
   Liver Health Screening Events
   Partner Events
42 International #NASHDay 2023 Sponsors
44 Appendix: Full List of Partners
MESSAGE
FROM
THE CEO
The prevalence of NAFLD and NASH has surged in recent years due to the effects of modern lifestyle choices and dietary patterns that have spread beyond developed countries to low- and middle-income countries as well. This has launched fatty liver disease to become the leading cause of chronic liver disease worldwide. As such, NASH is emerging as a critical global health priority that requires us all to step up to address it.

On International NASH Day this year, we stood united in an unwavering commitment to confront the disease head-on. For the hundred million individuals grappling with NASH today – and the many times more who are in precursor stages – this is a watershed moment.

Healthcare providers shared their expertise with their peers to increase screening rates and early diagnoses for at-risk individuals. Nonprofit organizations organized grassroots activities through walks, bike rides, and other events to encourage their communities to change their lifestyles to prevent fatty liver disease and advocate for screening. Patients and caregivers around the world received and shared new resources to navigate the patient journey in 18 languages. Regulatory agencies began to prioritize the patient point of view and the value of noninvasive tests in the approval process as momentum towards new treatments. Industry leaders amplified their support of the patients they serve by supporting awareness efforts.

Each and every one of these efforts is essential to stem the growing tide of NASH in communities around the world.

On behalf of the GLI team and its entire network, I thank every single person who stepped up this June. You showed up in force: Over 100 partners, in 55 countries, and 31 endorsing organizations joined together to recognize that NASH is a serious problem for our world and to take concrete steps to combat it. Through global participation, we garnered over 10 million impressions, while our news releases successfully reached thousands of journalists and their readers worldwide.

International NASH Day continues to grow each year, meeting the demand for timely liver health information. I express my deepest gratitude to all who contributed to the tremendous success of the 6th Annual International NASH Day. With our collective efforts, we will make significant strides in fighting this debilitating disease.

Donna R. Cryer, JD
Founder and CEO
Global Liver Institute
International #NASHDay June 8, 2023

>10 MILLION
#NASHDay Impressions

3.5 BILLION
Press Release
Potential Reach

11
Sponsors

>4M
#NASHDay Reach
106 NASH Day Partners

~35 Global Grassroots Events

31 Endorsers (Scientific Societies & International Organizations)

55 Countries

6 NASH Educational Panels and Videos
## Scientific Societies and International Organizations

1. American Association for the Study of Liver Diseases (AASLD)
2. Association of Black Gastroenterologists and Hepatologists (ABGH)
3. Asociación Argentina de Nutrición Enteral y Parenteral (AANEP)
4. American Gastroenterological Association (AGA)
5. Associazione Italiana Studio del Fegato (AISF)
6. Asociación Latinoamericana para el Estudio del Hígado (ALEH)
7. Asociación Mexicana de Hepatología (AMH)
8. Asian Pacific Association for the Study of the Liver (APASL)
9. Canadian Association for the Study of the Liver (CASL)
10. Conference on Liver Disease in Africa (COLDA)
11. European Association for the Study of the Liver (EASL)
12. European African Treatment Advocates Network (EATAN)
13. European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)
14. Fondazione Epatocentro Ticino
15. Gastroenterología y Endoscopía Digestiva de Costa Rica
16. Hepatology Society, Dhaka, Bangladesh (HSP)
17. Hepatology Society of the Philippines (INASL)
18. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)
21. Sociedad Argentina de Hepatología (SAHE)
22. Sociedade Brasileira de Hepatologia (SBH)
23. Sociedad Cubana de Gastroenterología (SOLDA)
24. Society on Liver Disease in Africa (SLSG)
25. Turkish Association for the Study of the Liver (TASL)
26. United European Gastroenterology (UEG)
27. World Gastroenterology Organisation (WGO)
28. World Obesity Federation
29. World Patients Alliance (WPA)
NASH Day 2023 was endorsed by 31 scientific societies and international organizations.
Countries and Territories Represented in Partner and Attendee Registrations
1. Algeria
2. Argentina
3. Australia
4. Austria
5. Bangladesh
6. Belgium
7. Bolivia
8. Bosnia and Herzegovina
9. Brazil
10. Cameroon
11. Canada
12. Chile
13. Colombia
14. Costa Rica
15. Croatia
16. Cuba
17. Cyprus
18. Denmark
19. Dominican Republic
20. Ecuador
21. Egypt
22. Finland
23. France
24. Germany
25. Georgia
26. Ghana
27. Greece
28. Guatemala
29. Honduras
30. India
31. Italy
32. Japan
33. Kenya
34. Lebanon
35. Macedonia
36. Mexico
37. Panama
38. Paraguay
39. Peru
40. Philippines
41. Portugal
42. Puerto Rico
43. Saudi Arabia
44. Slovenia
45. South Africa
46. Spain
47. Sri Lanka
48. Sweden
49. Switzerland
50. Turkey
51. Uganda
52. Uruguay
53. United Kingdom
54. United States
55. Venezuela
Patients’ Organizations and Foundations

- Associação Portuguesa para Estudo do Fígado (Portugal)
- PBC Foundation (UK)
- Canadian Liver Foundation (Canada)
- Christian Community Healthcare Foundation (Kenya)
- Community Nutrition Forum - Community of Dietitian’s in Kerala (India)
- Deutsche Leberhilfe (Germany)
- DiaLeb - National Diabetes Organization (Lebanon)
- Dutch Liver Patient Association (Netherlands)
- Empowerment for Sustainable Livelihood (Ghana)
- Empower Women Foundation (Cameroon)
- European Liver Patients Association (Belgium)
- Fatty Liver Alliance (Canada)
- Fatty Liver Foundation (USA)
- Federación Nacional de Enfermos y Trasplantados Hepáticos (México)
- The Finnish Kidney and Liver Association (Finland)
- Fundación Mexicana para la Salud Hepática (México)
- Helpas Prometheus (Hellenic Liver Patients Association) (Greece)
- Hepatitis Aid Austria - Platform Healthy Liver (HAA) (Austria)
- Hepatitis B Foundation (USA)
- Hepatitis B Initiative DC (USA)
- HEPYAŞAM - Living with Hepatitis Association (Türkiye)
- Hepatitis Queensland (Australia)
- Hepatos (Croatia)
- iHelpC (USA)
- Liver Health Foundation (USA)
- LiverNut (Argentina)
- Liver Patients International (Belgium)
- Friends of Liver Foundation West Bengal (USA)
- Mid-South Liver Alliance (USA)
- NASH 24x7 (India)
- NASH kNOWledge (USA)
- National Liver Foundation of Bangladesh (Bangladesh)
- Northeast Ohio Liver Alliance (USA)
- Rare Disease Uganda (Uganda)
- Türk Karaciğer Vakfı (Turkish Liver Foundation) (Türkiye)
- Texas Liver Foundation (USA)
- Value Health Africa (Cameroon)
Universities, Hospitals and Research Centers

- Alberta Diabetes Institute (Canada)
- Ashirwad Diabetes Care Center (India)
- Aster MIMS Hospital (India)
- Arizona Liver Health (USA)
- Centre Hospitalier de Tourcoing (France)
- Centro De Investigación y Gastroenterología (México)
- Cleveland Clinic (USA)
- Duke University (USA)
- Excel Gastro Care (India)
- Guy's and St. Thomas' Hospital (UK)
- Hospital Central "Dr. Ignacio Morones Prieto" (México)
- Hospital Israelita Albert Einstein (Brazil)
- Houston Methodist Hospital (USA)
- Houston Research Institute (USA)
- Impact Research Institute (USA)
- JSS Academy of Higher Education & Research (India)
- Mayo Clinic (USA)
- Penn State (USA)
- Pinnacle Clinical Research (USA)
- Resonance Health (USA)
- South Texas Research Institute (USA)
- Stanford Center for Continuing Medical Education (USA)
- Sultan Bin Abdulaziz Humanitarian City (Saudi Arabia)
- Summit Clinical Research (USA)
- Texas A&M School of Medicine (USA)
- University College London (UK)
- University of Alberta (Canada)
- University of Cincinnati Hospital (USA)
- University of Oxford (UK)
- University of Pennsylvania (USA)
- University of Washington (USA)
- VA Richmond Health Care System (USA)

Additional Partners

- Avant Santé
- Cardiometabolic
- Health Congress
- EtCurae
- Inventiva
- The Kinetix Group
- NASH Net
- Sharecare
- Surfing the NASH Tsunami
NASH: Are You at Risk?

“NASH: Are You at Risk?” is a new animated video created to raise awareness about NASH and its risk factors. The video emphasizes the importance of early detection and aims to inform, empower, and provide a sense of solidarity to viewers, equipping them with knowledge about NASH and encouraging them to take proactive steps for their liver health.
Pathway to Liver Health

A Conversation with Arizona Liver Health

In this interview, viewers are treated to an engaging visit and discussion featuring Donna R. Cryer, JD, Founder and CEO of Global Liver Institute, and Dr. Naim Alkhouri, CMO of Arizona Liver Health, a member of GLI’s Liver Action Network. The focus of their conversation lies in shedding light on the transformative impact of a patient-centered approach in liver healthcare.

The audience joins a journey to discover how Arizona Liver Health has successfully positioned itself as a convenient one-stop shop, simplifying the process of patient navigation. By delving into the strategies, services, and collaborative efforts that have propelled Arizona Liver Health to excel in their mission, viewers gain invaluable insights into the comprehensive care and support provided to patients.

5 Things You Need to Know About NASH

GLI, in collaboration with ShareCare, produced a short video highlighting five key facts an individual should know about NASH in order to raise awareness and encourage early detection and management of the disease.

Stills from “5 Things You Need to Know about NASH”
EDUCATIONAL PANELS

Overview

International NASH Day convenes physicians, advocates, and other experts to share the latest insights on how to prevent, diagnose, and manage fatty liver disease. An informed worldwide community is essential to reduce the global prevalence of fatty liver disease, which can advance dangerously if left undetected and unacknowledged. Thus, on June 8, GLI hosted 3 virtual educational panels featuring key opinion leaders, clinical, research, and patient experts in liver disease, nutrition, and public health to share actionable ways to support patients already diagnosed with NASH and to seek methods of risk reduction and prevention.
State of NASH
Putting All the Steps in Place

Donna R. Cryer, Founder and CEO of Global Liver Institute, hosted a panel discussion with experts in the field on the current state of NASH diagnosis, treatment, and awareness, including the new clinical care guidelines. The panelists addressed tactics to encourage screening among at-risk individuals, the role of non-invasive tests in clinical care, and steps to eliminate barriers to access for NASH patients. They emphasized the need for **equitable care**, **patient education**, **diverse representation in clinical trials**, and **collaboration between stakeholders**.

**MODERATOR**

Donna R. Cryer, JD  
Founder & CEO  
Global Liver Institute

**PANELIST**

Stephen Harrison, MD, FACP, FAASLD  
Chairman and Co-Founder, Summit Clinical Research  
Chairman and Founder, Pinnacle Clinical Research  
Visiting Professor of Hepatology  
Radcliffe Department of Medicine

Karen Hoyt  
Educator, Patient Advocate  
Founder, ihelpc LLC

Mazen Noureddin, MD, MHSc  
Professor of Medicine & Transplant Hepatologist  
Houston Methodist Hospital  
Director Houston Research Institute

Jude Oben, BM, BCh(Oxon), PhD, FRCP, FRCPE, AGAF  
Consultant, Guy’s and St Thomas’ Hospital  
Associate Professor in Hepatology, University College London
EXPLORING THE IMPACT OF NASH ON HIGH-RISK POPULATIONS

In this panel, Donna R. Cryer, Founder and CEO of Global Liver Institute, hosted a panel discussion on NASH and its impact on high-risk populations. Experts from around the world shared insights into NASH prevalence, risk factors, and long-term implications in specific communities such as Hispanic and Latino populations, veterans, patients with diabetes, and children. They explored the importance of early detection, healthcare access, cultural competency, and collaborative efforts to improve outcomes.

MODERATOR

Donna R. Cryer, JD
Founder & CEO
Global Liver Institute

PANELIST

Diana Mager, PhD, MSc, RD
Professor of Clinical Nutrition
Department of Pediatrics
Alberta Diabetes Institute
University of Oxford, UK

Puneet Puri, MD
Gastroenterologist
Hunter Holmes McGuire Veterans Affairs Medical Center-Richmond

Jorge Emilio Lira Vera, MD
Hepatologist, Gastroenterologist
Head of Liver Clinic
Hospital Central “Dr. Ignacio Morones Prieto”
LEVELING THE PLAYING FIELD
Ensuring Access to NASH Treatments in Black Communities

This guest panel discussion, hosted by the Association of Black Gastroenterologists and Hepatologists (ABGH), educated viewers about access to therapeutics for NASH and NASH-related conditions in Black communities. The panelists, including experts and a patient with NASH, discussed the burden of NASH in the Black adult population, shared personal experiences, explored the current treatments available, highlighted the underrepresentation of Black patients in clinical trials, and proposed strategies to improve access to care.

MODERATOR
Donna R. Cryer, JD
Founder & CEO
Global Liver Institute

PANELIST
Rotonya M. Carr, MD, FACP
Associate Professor of Medicine
Cyrus E. Rubin Endowed Chair in Medicine,
Division Head of Gastroenterology,
University of Washington

Victoria Arce
Patient Advocate
Independent Provider for the Mentally Disabled
University of Oxford, UK

Nadege T. Gunn, MD, CPI
Medical Director and President, Impact Research
Institute Adjunct Assistant Professor
Texas A & M School of Medicine

Octavia Pickett-Blakely MD, MHS
Associate Professor of Clinical Medicine
University of Pennsylvania

Julius Wilder, MD, PhD
Assistant Professor
Duke School of Medicine

Rickesha L. Wilson, MD
General and Bariatric Surgeon
Cleveland Clinic
THE GLOBAL PREVALENCE OF NAFLD IS FORECASTED TO REACH...

NIH, 2023
ENCE OF NAFLD IS EXPECTED TO REACH 55% BY 2040.
Under the theme of “#StepUpForNASH,” a powerful call to action was initiated by GLI to raise awareness about the significance of physical movement and its health benefits in reducing NASH. Through encouraging community involvement, GLI challenged individuals to embrace outdoor activities by walking up a flight of stairs or engaging in incline hikes. By emphasizing the simple act of “stepping up,” this campaign aimed to highlight the positive impact that physical activity can have on NASH prevention and management.

Through this call to action, GLI aimed to inspire individuals to take small yet impactful steps towards a healthier lifestyle, reinforcing the importance of incorporating exercise into daily routines for well-being – especially for individuals affected by NASH.
#NASHDay analytics

- Instagram
- Facebook
- LinkedIn

Reach: 4M
Impressions: 10M

KEYWORDS:
NASH, International, Liver, Disease, Awareness

Press Release
Text Potential Reach: 3.5B
Full text placements: 800
Headline placements: 179
Social Media Toolkit

To stimulate the circulation of important information and engaging discussions, Global Liver Institute created a digital toolkit for social media available in three languages: English, French, and Spanish.
The toolkit also included a newly designed table tent, poster, and roll up banner that partners could use.
Educational Materials

GLI released a new educational brochure: “Know Your Liver Labs,” a comprehensive resource aimed to increase and promote patient knowledge and expand the use of noninvasive diagnostics. The goal is to recognize and reduce gaps in care by equipping patients with the tools they need to properly interpret lab results and to empower patients to engage in conversations with their healthcare providers and become proactively involved in their own care management.

GLI’s NAFLD/NASH resources are now available in 18 languages, including the recent additions of Korean and Tagalog. Given that NAFLD/NASH are progressive, chronic, life-threatening, and global diseases, these brochures serve as valuable tools for patients and stakeholders worldwide.

Resources are available in Arabic, Chinese, Croatian, English, French, German, Greek, Hebrew, Hindi, Italian, Japanese, Korean, Macedonian, Portuguese, Russian, Spanish, Tagalog, and Turkish.
NASH DAY PARTNER HIGHLIGHTS
**CANADA | Fatty Liver Alliance**

Fatty Liver Alliance **organized a series of activities on NASH Day.**

The first event took place in London, Ontario, where a liver health screening day was held, and 29 individuals were assessed.

The second event took place in Montreal, Quebec, where hepatologists, primary care physicians, endocrinologists, and an epidemiologist convened to discuss clinical referral pathways, give presentations, and join engaging discussions.

Additionally, the Fatty Liver Alliance participated in two other educational events, including an episode of GLI LIVE and an online event.

---

**ARIZONA, USA | Arizona Liver Health**

The Arizona Liver Health Team **conducted over 120 free liver health screenings** across the state and provided comprehensive patient education at their three liver clinic locations.
NASH kNOWledge hosted an event targeted at key opinion leaders and individuals working in the Pittsburgh Hispanic/Latino community held at the Roberto Clemente Museum in Pittsburgh. The event featured a light dinner, informative speakers, and the distribution of educational materials.

Texas Liver Foundation hosted a social media campaign, publishing engaging posts on various platforms, along with a blog and newsletter, to promote International NASH Day. The content focused on providing a basic understanding of the disease and offering recommendations regarding diet and exercise.
Mid South Liver Alliance held an invitation-only Liver Update Educational Symposium in Birmingham, Alabama. The event was exclusively designed for hepatologists, GIs, PCPs, NPs, RNs, and PAs working with liver disease. The program commenced with a 45-minute networking experience, followed by a seated dinner and informative presentations. Dr. Meagan Gray and Dr. Fernando Ovalle from the University of Alabama at Birmingham delivered a talk on NAFLD/NASH, emphasizing the connection between diabetes, nutrition, and the metabolic system.
AFRICA

CAMEROON  |  Value Health Africa

Value Health Africa organized a two-day event, educating health workers and conducting free screenings for diabetes, hypertension, and BMI in the Nkwen Health Center and Mendankwe District Hospital. The screenings identified 7 cases of type 2 diabetes, 5 cases of hypertension, and 60 cases of obesity. These efforts aim to reduce the impact of NASH in the community.
KENYA  l  Christian Community Healthcare Foundation (COHECF)

The Christian Community Healthcare Foundation conducted a training session for over 100 trainees from Kenya Medical Training College in Kitale. These trainees regularly interact with patients at Kitale Referral Hospital and District Hospital and so the program aims to enhance their skills and knowledge on how to manage patients with NAFLD and NASH.

CAMEROON  l  Empower Women Foundation

Empower Women Foundation (EWF) heightened community awareness about NASH, stressing the significance of exercise in prevention. Participants, including patients, doctors, sonographers, and public health experts, attended presentations, discussions, and physical activities. They also committed to knowledge-sharing and enhancing NASH management. The event resulted in the creation of the EWF Liver Health Hub, along with plans for a doctor’s pocket guide and sonographer training.
INDIA  I  Ashirwad Diabetes Care Center

The Ashirwad Diabetes Care Center hosted 2 events on behalf of NASH day. An education and awareness event, followed by a health day with NASH screening, diabetes testing, and more. A total of 64 patients were screened, indicating they were all within high risk categories for NAFLD/NASH diagnosis.

INDIA  I  Community Nutrition Forum & Aster MIMS Hospital

The Community Nutrition Forum organized a state-level symposium to address NASH at the Aster MIMS Hospital, to raise awareness, promote education, and foster innovative strategies for its management and prevention. Experts, researchers, and healthcare professionals convened to exchange ideas and discuss evidence-based interventions, with a focus on personalized nutrition and nutrition interventions for NASH, ultimately striving for a healthier future through prevention and early intervention.
BANGLADESH  |  National Liver Foundation, Bangladesh

The National Liver Foundation of Bangladesh (NLFB) held an educational program for Medical Students of the Bangladesh Medical Students Society (BMSS) in Dhaka. They launched a brochure on NAFLD/NASH that was distributed to various medical institutions. Prof. Mohammad Ali, the foundation’s Secretary General, delivered the keynote speech and engaged in a question-answer session. Additionally, the foundation organized a BMI scale setup for the public, published a newspaper article, and participated in a televised talk show on NASH Day.

BANGLADESH  |  Hepatology Society of Dhaka, Bangladesh

The Hepatology Society Dhaka, Bangladesh, organized various programs to raise public awareness. They published a poster recommending a suitable diet and exercise plan for Bangladesh, provided training for primary care physicians, and hosted a roundtable discussion on the “Economic burden of fatty liver in Bangladesh,” attended by stakeholders from across the country.
JSS Academy of Higher Education & Research organized a walkathon to raise awareness about NAFLD and NASH. The event brought together over 300 participants, including national and international students, community members and faculty.

INASL and Rotary International collaboratively spearheaded a series of successful initiatives including the deployment of NAFLD/NASH awareness standees with QR Codes for liver health assessment, garnering 69,000 scans. Additionally, they launched the ROCCO (Rotary Combating Childhood Obesity and Fatty Liver) initiative for combating childhood obesity to screen children in schools, conducted press conferences at 47 locations, held 213 awareness meetings, organized 440 liver testing camps, promoted NASH awareness through a painting competition and featured a special issue in The Week magazine to boost community awareness.
OCEANIA

AUSTRALIA  I  Hepatitis Queensland

Hepatitis Queensland **developed a new suite of patient resources for NAFLD and NASH** in response to requests from healthcare professionals and patients during their Liver Smart clinics. Recognizing the limited availability of patient resources, they collaborated with clinical specialists to address this gap. After undergoing clinical review, the resources launched on International NASH Day.

CENTRAL AND SOUTH AMERICA

ARGENTINA  I  Asociación Argentina de Nutrición Enteral y Parenteral (AANEP)

AANEP **hosted a webinar** featuring a panel of experts including a hepatologist, clinical diabetologist, and nutritionist. Taking a multidisciplinary approach, the conversation focused on NASH, cirrhosis, transplantation, and HCC conditions in Argentina’s medical centers and hospitals.
BRAZIL  | Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein organized a hybrid event, blending virtual and in-person discussions. Esteemed nutritionists, nurses, doctors, fellows, and physical trainers contributed their expertise.

To further raise awareness of the disease, the hospital had an active online presence and disseminated NASH-related educational content.

EUROPE

BELGIUM  | European Liver Patients’ Association (ELPA)

ELPA organized the European NASH Summit entitled “Fatty Liver, is this another pandemic? For a healthier future, for our children,” at the European Parliament. Guest speakers, including representatives from GLI, addressed various perspectives on fatty liver disease, with discussions covering political, scientific, patient, and preventive aspects, underlining the imperative of joint global efforts to combat liver disease.
FINLAND  I  Finnish Kidney & Liver Association

The Kidney and Liver Association hosted “Finnish liver week” to raise awareness about fatty liver disease. The week included educational activities with tailored training for healthcare professionals, in partnership with Tampere University Hospital and other experts. A public lecture on NAFLD/NASH and a panel discussion on the personal impact of liver disease was also organized.

To maximize outreach, the association issued three media releases and leveraged social media throughout the week.

GREECE  I  Hellenic Liver Patients Association “Prometheus”

The Hellenic Liver Patients Association raised awareness about fatty liver disease and emphasized its prevention through a robust social media campaign. Posts included information about NASH, symptom recognition, main risk factors, and preventive measures.

Through targeted advertising, it successfully reached 3,058 individuals.

NETHERLANDS  I  Nederlandse Leverpatienten Vereniging / Dutch Liver Patients Association

The Dutch Liver Patients Association led a focused social media campaign to raise awareness about NAFLD. The campaign highlighted lifestyle improvement tips and preventive measures to combat this condition.
MIDDLE EAST

LEBANON  l  DiaLeb - National Diabetes Organization

Under the esteemed patronage of H.E. Lebanese Minister of Public Health, Dr. Firas Abiad, DiaLeb, in collaboration with Global Liver Institute, organized a health day for NASH Day, followed by a lecture at the American University of Beirut. In partnership with the International Diabetes Federation MENA, Lebanese Medical Students’ International Committee, Faculty of Agriculture and Food Sciences, and the Lebanese Order of Dietitians, the event offered 283 blood glucose tests, 40 HbA1c tests, and 67 nutrition consultations and body composition assessments. The lecture featured remarks and presentations from key figures and experts, attracting a diverse audience of >350 individuals including medical students, dietitians, individuals with type 2 diabetes, and the public.

DiaLeb also had 2 interviews on national TV channels, sent out a press release in both English and Arabic and received coverage on multiple news websites.

TÜRKIYE  l  TASL - Turkish Association for the Study of the Liver

TASL offered free FibroScan screenings to the public, aiming to raise awareness about fatty liver disease and enable early diagnosis and effective treatment, not just in Turkey but also in wider regions. TASL also had multiple interviews on national TV channels, they were mentioned in various print media. Leveraging social media, TASL amplified their reach with informative NASH content.
The Hepyaşam Association held events in Istanbul, featuring a public meeting with specialists and families of disabled children, sports activities with a NASH display, informative videos, advocacy efforts, and widespread promotion on social media channels.

NORTH AMERICA

USA  l  Mayo Clinic

The Mayo Clinic Division of Gastroenterology/Hepatology, under the guidance of Dr. Manal Abdelmalek, held a media launch, marketing strategies for heightened NAFLD/NASH awareness, and the introduction of emerging therapies. Utilizing various resources such as video education, printed materials, and FibroScan access, they effectively communicated with patients and raised awareness about fatty liver disease. Furthermore, they partnered with diverse interest groups to host the Mayo NASH Symposium.
USA  I  Richmond VA Medical Center

The Hepatology department at the Richmond VA Medical Center organized an informative event addressing the global concern of metabolic-related fatty liver disease. Attendees were educated about the disease, its prevalence, and personal risk factors. Participants had the opportunity to engage with healthcare professionals, discuss diet and exercise, consult with a dietician, and undergo liver scans, all geared towards empowering individuals to take proactive steps for their liver health.

MEXICO  I  FundHepa

FundHepa organized a public zumba class with 87 attendees to raise awareness about the significance of physical movement in combating NASH.

USA  I  Impact Research Institute

Impact Research Institute organized a comprehensive and multifaceted liver health screening event at their facility, aiming to provide thorough and advanced diagnostic services.
USA  I  Summit Clinical Research

The team at Summit Clinical Research led a campaign to elevate awareness for fatty liver disease. Under the theme of “Kick Some NASH,” they underscored the pivotal significance of clinical research in combating this pressing health challenge.

USA  I  American Gastroenterological Association

GLI was a part of the American Association of Gastroenterologists Congressional briefing on Capitol Hill, emphasizing the link between obesity and NAFLD/NASH. Representative Brad Wenstrup, DPM, (R-OH) led the event, advocating for the advancement of the Treat and Reduce Obesity Act (TROA) to enhance access to obesity care and treatment under Medicare.

USA  I  Madrigal Pharmaceuticals

The Madrigal Pharmaceuticals team visited the iconic “Rocky Steps” in Philadelphia to #StepUpforNASH, emphasizing the importance of physical activity in NASH reduction.
CIG Mexico’s dynamic team organized a 4K Run themed “Reto vs. Higado Grado,” aiming to promote physical activity and raise awareness about the role of exercise in combating fatty liver disease and NASH. Additionally, CIG hosted a NAFLD Forum at the House of Mexico House of Congress, led by Lic. Ricardo Monreal and Lic. Emanuel Reyes, gathering 150 attendees including community representatives, physicians, associations, and policymakers dedicated to shaping public policy for fatty liver disease prevention in the country.

The Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, in partnership with Avant Santé and EtCurae, organized a multi-day conference. Educational panels and presentations, intended for medical professionals, were led by experts from around the world in gastroenterology, hepatology, metabolic health, immunology, and more - focused on fatty liver disease treatment options in Mexico.
USA  |  Friends of Liver Foundation, West Bengal

The Friends of Liver Foundation, West Bengal created and disseminated NASH informational flyers and bookmarks in public libraries across prominent locations such as the Bay Area, CA, Dallas, TX, and St. Louis, MO. Their outreach extended to online platforms including LinkedIn, WhatsApp, and email distribution, ensuring a broader and more inclusive audience.

MEXICO  |  Hospital Central “Dr. Ignacio Morones Prieto”

Hospital Central’s team organized an educational panel featuring hepatologists and gastroenterologists from the liver clinic. The discussion revolved around the influence of gut microbiome on NASH, non-invasive diagnostic methods, treatment approaches, and the correlation between alcohol and NASH. The audience included physicians and residents from the Internal Medicine division of the hospital.
Global Liver Institute is grateful for the leadership and generous contributions of our sponsors whose support makes International NASH Day possible.
Platinum

Gold

Silver

Bronze

Contributors
## APPENDIX

### Full List of Partners

<table>
<thead>
<tr>
<th>Organization</th>
<th>City</th>
<th>State/Province</th>
<th>Country</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASLD - American Association for the Study of Liver Diseases</td>
<td>Alexandria</td>
<td>Virginia</td>
<td>USA</td>
<td><a href="https://www.aasld.org">https://www.aasld.org</a></td>
</tr>
<tr>
<td>AGA - American Gastroenterological Association</td>
<td>Bethesda</td>
<td>Maryland</td>
<td>USA</td>
<td><a href="https://gastro.org/">https://gastro.org/</a></td>
</tr>
<tr>
<td>Arizona Liver Health</td>
<td>Chandler, Peoria, Tucson</td>
<td>Arizona</td>
<td>USA</td>
<td><a href="https://www.azliver.com">https://www.azliver.com</a></td>
</tr>
<tr>
<td>Ashirwad Diabetes Care Center</td>
<td>Dahanu Road</td>
<td>Maharashtra</td>
<td>India</td>
<td><a href="https://ashirwadclinic.com/">https://ashirwadclinic.com/</a></td>
</tr>
<tr>
<td>APASL - Asia Pacific Association for the Study of the Liver</td>
<td>Kyoto</td>
<td></td>
<td>Japan</td>
<td><a href="https://www.aanep.org.ar/es/">https://www.aanep.org.ar/es/</a></td>
</tr>
<tr>
<td>AANEP - Asociaciòn Argentina de Nutrición Enterado y Parenteral</td>
<td>Buenos Aires</td>
<td></td>
<td>Argentina</td>
<td><a href="https://alehlatam.org/">https://alehlatam.org/</a></td>
</tr>
<tr>
<td>ALEH - Asociaciòn Latinoamericana para el Estudio del Hígado</td>
<td>Santiago de Chile</td>
<td></td>
<td>Chile</td>
<td><a href="https://www.hepatologia.org.mx">https://www.hepatologia.org.mx</a></td>
</tr>
<tr>
<td>ABGH - Association of Black Gastroenterologists and Hepatologists</td>
<td>New York</td>
<td>New York</td>
<td>USA</td>
<td><a href="https://blackingastro.org/">https://blackingastro.org/</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
<td>---------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Aster MIMS Hospital</td>
<td>Kozhikode</td>
<td>Kerala</td>
<td>India</td>
<td><a href="https://www.asterhospitals.in/hospitals/aster-mims-calicut">https://www.asterhospitals.in/hospitals/aster-mims-calicut</a></td>
</tr>
<tr>
<td>Avant Sante</td>
<td>San Pedro Garza García</td>
<td>Nuevo León</td>
<td>Mexico</td>
<td><a href="https://www.avantsante.com/">https://www.avantsante.com/</a></td>
</tr>
<tr>
<td>CASL - Canadian Association for the Study of the Liver</td>
<td>Edmonton</td>
<td>Alberta</td>
<td>Canada</td>
<td><a href="https://hepatology.ca/">https://hepatology.ca/</a></td>
</tr>
<tr>
<td>CLF - Canadian Liver Foundation</td>
<td>Toronto</td>
<td>Ontario</td>
<td>Canada</td>
<td><a href="https://www.liver.ca">https://www.liver.ca</a></td>
</tr>
<tr>
<td>Cardiometabolic Health Congress</td>
<td>Boca Raton</td>
<td>Florida</td>
<td>USA</td>
<td><a href="https://www.cardiometabolichealth.org/">https://www.cardiometabolichealth.org/</a></td>
</tr>
<tr>
<td>Centre Hospitalier de Tourcoing</td>
<td>Tourcoing</td>
<td></td>
<td>France</td>
<td><a href="https://www.ch-tourcoing.fr/">https://www.ch-tourcoing.fr/</a></td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Ingelheim am Rhein</td>
<td></td>
<td>Germany</td>
<td><a href="https://www.boehringer-ingelheim.com/">https://www.boehringer-ingelheim.com/</a></td>
</tr>
<tr>
<td>CIG - Centro de Investigación y Gastroenterología</td>
<td>Mexico City</td>
<td></td>
<td>Mexico</td>
<td><a href="https://www.centrodeinvestigacionygastroenterologia.com.mx">https://www.centrodeinvestigacionygastroenterologia.com.mx</a></td>
</tr>
<tr>
<td>Cleveland Clinic</td>
<td>Kitale</td>
<td></td>
<td>Ohio</td>
<td><a href="https://my.clevelandclinic.org/">https://my.clevelandclinic.org/</a></td>
</tr>
<tr>
<td>COLDA 2023- Conference on Liver Disease in Africa</td>
<td>Utrecht</td>
<td></td>
<td>Netherlands</td>
<td><a href="https://academicmedicineeducation.com/colda-2023">https://academicmedicineeducation.com/colda-2023</a></td>
</tr>
<tr>
<td>Deutsche Leberhilfe</td>
<td>Köln</td>
<td></td>
<td>Germany</td>
<td><a href="https://www.leberhilfe.org">https://www.leberhilfe.org</a></td>
</tr>
<tr>
<td>DiaLeb - National Diabetes Organization</td>
<td>Jdeideh</td>
<td></td>
<td>Lebanon</td>
<td><a href="https://dialeb.org/">https://dialeb.org/</a></td>
</tr>
<tr>
<td>Duke University Medical Center</td>
<td>Durham</td>
<td>North Carolina</td>
<td></td>
<td><a href="https://www.dukehealth.org/">https://www.dukehealth.org/</a></td>
</tr>
<tr>
<td>Dutch Liver Patients Association</td>
<td>Hoogland</td>
<td></td>
<td>Netherlands</td>
<td><a href="http://www.leverpatientenzvereniging.nl/">http://www.leverpatientenzvereniging.nl/</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>---------------------</td>
<td>-------------------------</td>
<td>---------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Empower Women Foundation</td>
<td></td>
<td></td>
<td>Cameroon</td>
<td><a href="https://www.facebook.com/foundation.empower-women/">https://www.facebook.com/foundation.empower-women/</a></td>
</tr>
<tr>
<td>EFSL - Empowerment for Sustainable Livelihood</td>
<td>Accra</td>
<td></td>
<td>Ghana</td>
<td><a href="https://www.facebook.com/efslgh">https://www.facebook.com/efslgh</a></td>
</tr>
<tr>
<td>EtCurae</td>
<td>Mexico City</td>
<td></td>
<td>México</td>
<td><a href="https://etcurae.com/">https://etcurae.com/</a></td>
</tr>
<tr>
<td>EATAN - European African Treatment Advocates</td>
<td></td>
<td></td>
<td>EU</td>
<td><a href="https://www.eatan.eu/">https://www.eatan.eu/</a></td>
</tr>
<tr>
<td>Network</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EASL - European Association for the Study of the</td>
<td>Geneva</td>
<td></td>
<td>Switzerland</td>
<td><a href="https://easl.eu/">https://easl.eu/</a></td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELPA - European Liver Patients Association</td>
<td>Brussels</td>
<td></td>
<td>Belgium</td>
<td><a href="https://elpa.eu/">https://elpa.eu/</a></td>
</tr>
<tr>
<td>Equinox</td>
<td>Washington</td>
<td>District of Columbia</td>
<td>USA</td>
<td><a href="https://www.equinox.com/">https://www.equinox.com/</a></td>
</tr>
<tr>
<td>Excel Gastro Care</td>
<td>Kerala</td>
<td></td>
<td>India</td>
<td><a href="https://www.excelgastro-care.com/">https://www.excelgastro-care.com/</a></td>
</tr>
<tr>
<td>Fatty Liver Alliance</td>
<td></td>
<td></td>
<td></td>
<td><a href="https://fattyliver.ca/">https://fattyliver.ca/</a></td>
</tr>
<tr>
<td>FLF - Fatty Liver Foundation</td>
<td>Boise</td>
<td>Idaho</td>
<td>USA</td>
<td><a href="http://www.fattyliverfoundation.org/">http://www.fattyliverfoundation.org/</a></td>
</tr>
<tr>
<td>FNETH - Federación Nacional de Enfermos y</td>
<td>Madrid</td>
<td></td>
<td>Spain</td>
<td><a href="https://fneth.org/">https://fneth.org/</a></td>
</tr>
<tr>
<td>Trasplantados Hepáticos</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Finnish Kidney and Liver Association</td>
<td>Helsinki</td>
<td></td>
<td>Finland</td>
<td><a href="https://www.muma.fi/">https://www.muma.fi/</a></td>
</tr>
<tr>
<td>Fondazione Epatocentro Ticino</td>
<td>Lugano</td>
<td></td>
<td>Switzerland</td>
<td><a href="http://www.epatocentro.ch/en/">http://www.epatocentro.ch/en/</a></td>
</tr>
<tr>
<td>FLFWB - Friends of Liver Foundation West Bengal</td>
<td>Dublin</td>
<td></td>
<td>California</td>
<td><a href="https://friendsoffwb.org/">https://friendsoffwb.org/</a></td>
</tr>
<tr>
<td>FundHepa - Fundacion Mexicana para la Salud</td>
<td>Mexico City</td>
<td></td>
<td>Mexico</td>
<td><a href="https://fundhepa.org/">https://fundhepa.org/</a></td>
</tr>
<tr>
<td>Hepatica</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guy’s and St. Thomas’ Hospital</td>
<td>London</td>
<td></td>
<td>UK</td>
<td><a href="https://www.guysandstthom-as.nhs.uk/">https://www.guysandstthom-as.nhs.uk/</a></td>
</tr>
<tr>
<td>Helpa Prometheus (Hellenic Liver Patients</td>
<td>Athens</td>
<td></td>
<td>Greece</td>
<td><a href="https://helpa-prometheus.gr">https://helpa-prometheus.gr</a></td>
</tr>
<tr>
<td>Association)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------</td>
<td>----------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>HHÖ – Plattform Gesunde Leber (Hepatitis Aid Austria)</td>
<td>Doylestown</td>
<td>Pennsylvania</td>
<td>Austria</td>
<td><a href="https://www.gesundeleber.at/">https://www.gesundeleber.at/</a></td>
</tr>
<tr>
<td>Hepatitis B Foundation</td>
<td>Washington</td>
<td>District of Columbia</td>
<td>USA</td>
<td><a href="https://www.hepb.org/">https://www.hepb.org/</a></td>
</tr>
<tr>
<td>Hepatitis B Initiative - DC</td>
<td>Coorparoo</td>
<td>Queensland</td>
<td>Australia</td>
<td><a href="https://www.hepqld.asn.au/">https://www.hepqld.asn.au/</a></td>
</tr>
<tr>
<td>Hepatitis Queensland</td>
<td>Quezon City</td>
<td></td>
<td>Philippines</td>
<td><a href="http://hsp.org.ph/">http://hsp.org.ph/</a></td>
</tr>
<tr>
<td>HSP - Hepatology Society of the Philippines</td>
<td>Dhaka</td>
<td></td>
<td>Bangladesh</td>
<td><a href="http://www.hepatologysocietybd.org/">http://www.hepatologysocietybd.org/</a></td>
</tr>
<tr>
<td>Hepatology Society of Bangladesh</td>
<td>Split</td>
<td></td>
<td>Croatia</td>
<td><a href="https://hepatos.hr">https://hepatos.hr</a></td>
</tr>
<tr>
<td>HEPYAŞAM - Living with Hepatitis Association</td>
<td>Istanbul</td>
<td></td>
<td>Türkiye</td>
<td><a href="http://www.hepatitleyasam.org/">http://www.hepatitleyasam.org/</a></td>
</tr>
<tr>
<td>Hospital Central “Dr. Ignacio Morones Prieto”</td>
<td>San Luis Potosí</td>
<td></td>
<td>Mexico</td>
<td><a href="https://www.hospitalcentral.gob.mx/">https://www.hospitalcentral.gob.mx/</a></td>
</tr>
<tr>
<td>Hospital Israelita Albert Einstein</td>
<td>São Paulo</td>
<td></td>
<td>Brazil</td>
<td><a href="https://www.einstein.br/en/Pages/Home.aspx">https://www.einstein.br/en/Pages/Home.aspx</a></td>
</tr>
<tr>
<td>Houston Methodist Hospital</td>
<td>Houston</td>
<td>Texas</td>
<td>USA</td>
<td>houstonmethodist.org</td>
</tr>
<tr>
<td>iHelpC</td>
<td>Tulsa</td>
<td>Oklahoma</td>
<td>USA</td>
<td><a href="https://www.ihelpc.com/">https://www.ihelpc.com/</a></td>
</tr>
<tr>
<td>Impact Research Institute</td>
<td>Waco</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://impactresearchtx.com/">https://impactresearchtx.com/</a></td>
</tr>
<tr>
<td>INASL - Indian National Association for Study of the Liver</td>
<td>New Delhi</td>
<td></td>
<td>India</td>
<td><a href="https://gastroenterologosc.r.com/">https://gastroenterologosc.r.com/</a></td>
</tr>
<tr>
<td>INCMNSZ - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</td>
<td>Ciudad de</td>
<td>México</td>
<td>Mexico</td>
<td><a href="https://www.incmnsz.mx/opencms/">https://www.incmnsz.mx/opencms/</a></td>
</tr>
<tr>
<td>Inventiva</td>
<td></td>
<td></td>
<td>France</td>
<td><a href="https://inventivapharma.com/">https://inventivapharma.com/</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>The Kinetix Group</td>
<td>New York</td>
<td>New York</td>
<td>USA</td>
<td><a href="https://thekinetixgroup.com/">https://thekinetixgroup.com/</a></td>
</tr>
<tr>
<td>Liver Health Foundation</td>
<td>Irvine</td>
<td>California</td>
<td>USA</td>
<td><a href="https://www.liverhealthfoundations.org/">https://www.liverhealthfoundations.org/</a></td>
</tr>
<tr>
<td>LPI - Liver Patients International</td>
<td>Brussels</td>
<td></td>
<td>Belgium</td>
<td><a href="https://liverpatientsinternational.org/who-we-are">https://liverpatientsinternational.org/who-we-are</a></td>
</tr>
<tr>
<td>LiverNut</td>
<td>Santa Fe</td>
<td></td>
<td>Argentina</td>
<td><a href="https://livernut.com.ar/">https://livernut.com.ar/</a></td>
</tr>
<tr>
<td>Madrigal</td>
<td>West Conshohocken</td>
<td>Pennsylvania</td>
<td>USA</td>
<td><a href="https://www.madrigalpharma.com/">https://www.madrigalpharma.com/</a></td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>Rochester</td>
<td>Minnesota</td>
<td>USA</td>
<td><a href="https://www.alignable.com/nashville-tn/mid-south-liver-alliance">https://www.alignable.com/nashville-tn/mid-south-liver-alliance</a></td>
</tr>
<tr>
<td>Merck</td>
<td>Lebanon</td>
<td>New Jersey</td>
<td>USA</td>
<td><a href="https://www.merck.com/">https://www.merck.com/</a></td>
</tr>
<tr>
<td>Mid-South Liver Alliance</td>
<td>Nashville</td>
<td>Tennessee</td>
<td>USA</td>
<td><a href="https://www.alignable.com/nashville-tn/mid-south-liver-alliance">https://www.alignable.com/nashville-tn/mid-south-liver-alliance</a></td>
</tr>
<tr>
<td>NASH 24x7 Initiative</td>
<td></td>
<td></td>
<td>India</td>
<td><a href="https://www.nash24x7.com/">https://www.nash24x7.com/</a></td>
</tr>
<tr>
<td>NASH kNOWledge</td>
<td>Pittsburgh</td>
<td>Tennessee</td>
<td>USA</td>
<td><a href="https://www.nash-now.org">https://www.nash-now.org</a></td>
</tr>
<tr>
<td>NASH Net</td>
<td></td>
<td></td>
<td>USA</td>
<td><a href="https://nashnetwork.org/">https://nashnetwork.org/</a></td>
</tr>
<tr>
<td>National Liver Foundation of Bangladesh</td>
<td>Dhaka</td>
<td>Bangladesh</td>
<td></td>
<td><a href="https://www.liver.org.bd/">https://www.liver.org.bd/</a></td>
</tr>
<tr>
<td>Nike</td>
<td>Beaverton</td>
<td>Oregon</td>
<td>USA</td>
<td><a href="https://www.nike.com/">https://www.nike.com/</a></td>
</tr>
<tr>
<td>Northeast Ohio Liver Alliance</td>
<td></td>
<td>Ohio</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td></td>
<td></td>
<td>USA</td>
<td><a href="https://www.novonordisk-us.com/">https://www.novonordisk-us.com/</a></td>
</tr>
<tr>
<td>Nutristyle</td>
<td></td>
<td></td>
<td>USA</td>
<td><a href="https://nutristyle.com/">https://nutristyle.com/</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------</td>
<td>----------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PBC Foundation</td>
<td>Edinburgh</td>
<td></td>
<td>United Kingdom</td>
<td><a href="https://www.pbcfoundation.org.uk">https://www.pbcfoundation.org.uk</a></td>
</tr>
<tr>
<td>Penn State</td>
<td>State College</td>
<td>Pennsylvania</td>
<td>USA</td>
<td><a href="https://www.psu.edu/">https://www.psu.edu/</a></td>
</tr>
<tr>
<td>Pinnacle Clinical Research</td>
<td>San Antonio</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://www.pinnacleresearch.com/">https://www.pinnacleresearch.com/</a></td>
</tr>
<tr>
<td>Rare Disease Uganda</td>
<td>Soroti</td>
<td></td>
<td>Uganda</td>
<td><a href="https://www.ehlers-danlos.com/affiliate-and-support-group/rare-diseases-uganda-rdu/">https://www.ehlers-danlos.com/affiliate-and-support-group/rare-diseases-uganda-rdu/</a></td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td></td>
<td></td>
<td>USA</td>
<td><a href="https://www.regeneron.com/">https://www.regeneron.com/</a></td>
</tr>
<tr>
<td>Resonance Health</td>
<td></td>
<td></td>
<td>Australia</td>
<td><a href="https://www.resonancehealth.com/">https://www.resonancehealth.com/</a></td>
</tr>
<tr>
<td>Sharecare</td>
<td>Atlanta</td>
<td>Georgia</td>
<td>USA</td>
<td><a href="https://www.sharecare.com/">https://www.sharecare.com/</a></td>
</tr>
<tr>
<td>SAHE - Sociedad Argentina de Hepatologia</td>
<td>Buenos Aires</td>
<td></td>
<td>Argentina</td>
<td><a href="https://www.aaeh.org.ar/es/">https://www.aaeh.org.ar/es/</a></td>
</tr>
<tr>
<td>SBH - Sociedade Brasileira de Hepatologia</td>
<td>São Paulo</td>
<td></td>
<td>Brazil</td>
<td><a href="https://sbhepatologia.org.br/">https://sbhepatologia.org.br/</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>USA</td>
<td>houstonmethodist.org</td>
</tr>
<tr>
<td>SOLDA - Society on Liver Disease in Africa</td>
<td>Utrecht</td>
<td></td>
<td>Netherlands</td>
<td><a href="https://www.solda-society.org/">https://www.solda-society.org/</a></td>
</tr>
<tr>
<td>South Texas Research</td>
<td>Edinburg</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://southtexasresearchinstitute.com/">https://southtexasresearchinstitute.com/</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>--------------</td>
<td>----------------</td>
<td>---------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Stanford Center for Continuing Medical Education</td>
<td>Stanford</td>
<td>California</td>
<td>USA</td>
<td><a href="https://med.stanford.edu/cme.html">https://med.stanford.edu/cme.html</a></td>
</tr>
<tr>
<td>Sultan Bin Abdulaziz Humanitarian City</td>
<td>Riyadh</td>
<td></td>
<td>Saudi Arabia</td>
<td><a href="https://sbahc.org.sa/">https://sbahc.org.sa/</a></td>
</tr>
<tr>
<td>Summit Clinical Research</td>
<td>San Antonio</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://summitclinicalresearch.com/">https://summitclinicalresearch.com/</a></td>
</tr>
<tr>
<td>Surfing NASH</td>
<td></td>
<td></td>
<td>USA</td>
<td><a href="https://surfingnash.com/">https://surfingnash.com/</a></td>
</tr>
<tr>
<td>Terns Pharmaceutical</td>
<td>Foster City</td>
<td>California</td>
<td>USA</td>
<td><a href="https://www.ternspharma.com/">https://www.ternspharma.com/</a></td>
</tr>
<tr>
<td>Texas A&amp;M School of Medicine</td>
<td>Bryan</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://medicine.tamu.edu/index.html">https://medicine.tamu.edu/index.html</a></td>
</tr>
<tr>
<td>Texas Liver Foundation</td>
<td>Houston</td>
<td>Texas</td>
<td>USA</td>
<td><a href="https://www.texasliverfoundation.org/">https://www.texasliverfoundation.org/</a></td>
</tr>
<tr>
<td>Türk Karaciğer Vakfı (Turkish Liver Foundation)</td>
<td>Istanbul</td>
<td></td>
<td>Türkiye</td>
<td><a href="http://www.tkcv.org/">http://www.tkcv.org/</a></td>
</tr>
<tr>
<td>TASL - Turkish Association for the Study of the Liver</td>
<td>Istanbul</td>
<td></td>
<td>Türkiye</td>
<td><a href="https://www.tkad.org.tr/invitation">https://www.tkad.org.tr/invitation</a></td>
</tr>
<tr>
<td>UEG - United European Gastroenterology</td>
<td>Vienna</td>
<td></td>
<td>Austria</td>
<td><a href="https://ueg.eu">https://ueg.eu</a></td>
</tr>
<tr>
<td>University College London</td>
<td>London</td>
<td></td>
<td>United Kingdom</td>
<td><a href="https://www.ucl.ac.uk/">https://www.ucl.ac.uk/</a></td>
</tr>
<tr>
<td>University of Alberta</td>
<td></td>
<td>Alberta</td>
<td>Canada</td>
<td><a href="https://www.ualberta.ca/index.html">https://www.ualberta.ca/index.html</a></td>
</tr>
<tr>
<td>University of Cincinnati Hospital;</td>
<td>Cincinnati</td>
<td>Ohio</td>
<td>USA</td>
<td><a href="https://www.uchealth.com/en/locations/uc-medical-center">https://www.uchealth.com/en/locations/uc-medical-center</a></td>
</tr>
<tr>
<td>University of Oxford</td>
<td>Oxford</td>
<td></td>
<td>UK</td>
<td><a href="https://www.ox.ac.uk/">https://www.ox.ac.uk/</a></td>
</tr>
<tr>
<td>University of Pennsylvania</td>
<td>Philadelphia</td>
<td>Pennsylvania</td>
<td>USA</td>
<td><a href="https://www.upenn.edu/">https://www.upenn.edu/</a></td>
</tr>
<tr>
<td>University of Washington School of Medicine</td>
<td>Seattle</td>
<td>Washington</td>
<td>USA</td>
<td><a href="https://www.uwmedicine.org/school-of-medicine">https://www.uwmedicine.org/school-of-medicine</a></td>
</tr>
<tr>
<td>Organization</td>
<td>City</td>
<td>State/Province</td>
<td>Country</td>
<td>Website</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------</td>
<td>----------------</td>
<td>---------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>VA Richmond Healthcare</td>
<td>Richmond</td>
<td>Richmond</td>
<td>USA</td>
<td><a href="https://www.va.gov/richmond-health-care/">https://www.va.gov/richmond-health-care/</a></td>
</tr>
<tr>
<td>Value Health Africa</td>
<td>Buea</td>
<td></td>
<td>Cameroon</td>
<td><a href="http://www.valuehealthafrica.org/">http://www.valuehealthafrica.org/</a></td>
</tr>
<tr>
<td>WGO - World Gastroenterology</td>
<td>Wisconsin</td>
<td></td>
<td>USA</td>
<td><a href="https://www.worldgastroenterology.org/">https://www.worldgastroenterology.org/</a></td>
</tr>
<tr>
<td>Organisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Obesity Federation</td>
<td></td>
<td></td>
<td>UK</td>
<td><a href="https://www.worldobesity.org/">https://www.worldobesity.org/</a></td>
</tr>
<tr>
<td>WPA - World Patients Alliance</td>
<td>Washington</td>
<td>DC</td>
<td>USA</td>
<td><a href="https://www.worldpatientsalliance.org/">https://www.worldpatientsalliance.org/</a></td>
</tr>
<tr>
<td>Zydus Lifesciences</td>
<td>Ahmedabad</td>
<td>Gujarat</td>
<td>India</td>
<td><a href="https://zyduscadila.com/">https://zyduscadila.com/</a></td>
</tr>
</tbody>
</table>
Global Liver Institute is a 501(c)(3) tax exempt not-for-profit organization, with headquarters both in the United States and in Europe. Our mission is to improve the effectiveness of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver disease.

International NASH Day and its logo are a registered trademark of Global Liver Institute. This content is intended to provide helpful health information to the general public. This content is not intended as medical advice for individual problems. Global Liver Institute, including its board of directors and staff personnel, specifically disclaim all responsibility for any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the content.
IT ALL STARTS WITH A PATIENT